ATE313324T1 - Verwendung von brefeldin a und deren derivate in der herstellung von arzneimittel zur behandlung von hyperplasie und verwandten erkrankungen - Google Patents

Verwendung von brefeldin a und deren derivate in der herstellung von arzneimittel zur behandlung von hyperplasie und verwandten erkrankungen

Info

Publication number
ATE313324T1
ATE313324T1 AT96918159T AT96918159T ATE313324T1 AT E313324 T1 ATE313324 T1 AT E313324T1 AT 96918159 T AT96918159 T AT 96918159T AT 96918159 T AT96918159 T AT 96918159T AT E313324 T1 ATE313324 T1 AT E313324T1
Authority
AT
Austria
Prior art keywords
brefeldin
derivatives
hyperplasia
intimal hyperplasia
manufacturing
Prior art date
Application number
AT96918159T
Other languages
English (en)
Inventor
Charles E Hart
Connell Oliver J Mc
Theresa Martinez
Robert R West
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE313324T1 publication Critical patent/ATE313324T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96918159T 1995-06-07 1996-06-04 Verwendung von brefeldin a und deren derivate in der herstellung von arzneimittel zur behandlung von hyperplasie und verwandten erkrankungen ATE313324T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/483,216 US5618837A (en) 1995-06-07 1995-06-07 PDGF antagonists III
PCT/US1996/009061 WO1996040112A1 (en) 1995-06-07 1996-06-04 Use of brefeldin a and derivatives thereof in the treatment of hyperplasia and related disorders

Publications (1)

Publication Number Publication Date
ATE313324T1 true ATE313324T1 (de) 2006-01-15

Family

ID=23919165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918159T ATE313324T1 (de) 1995-06-07 1996-06-04 Verwendung von brefeldin a und deren derivate in der herstellung von arzneimittel zur behandlung von hyperplasie und verwandten erkrankungen

Country Status (9)

Country Link
US (1) US5618837A (de)
EP (1) EP0831807B1 (de)
JP (1) JP3190684B2 (de)
AT (1) ATE313324T1 (de)
AU (1) AU6048396A (de)
DE (1) DE69635614T2 (de)
DK (1) DK0831807T3 (de)
ES (1) ES2253750T3 (de)
WO (1) WO1996040112A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001512422A (ja) * 1997-02-05 2001-08-21 アレリツクス・フアーム−エコ・エル・ピー 記憶増強のための薬剤
WO1999031084A1 (en) 1997-12-18 1999-06-24 Purdue Research Foundation Brefeldin a derivatives
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
CA2424029C (en) 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
AU2001296558A1 (en) 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
CA2094858C (en) * 1992-04-28 2004-06-15 Robert D. Mitchell Method of treating hyperproliferative vascular disease
WO1995021614A1 (en) * 1994-02-09 1995-08-17 Ariad Pharmaceuticals, Inc. New protein trafficking inhibitors

Also Published As

Publication number Publication date
EP0831807A1 (de) 1998-04-01
DK0831807T3 (da) 2006-05-08
WO1996040112A1 (en) 1996-12-19
DE69635614D1 (de) 2006-01-26
EP0831807B1 (de) 2005-12-21
US5618837A (en) 1997-04-08
JP2000513703A (ja) 2000-10-17
DE69635614T2 (de) 2006-07-27
AU6048396A (en) 1996-12-30
JP3190684B2 (ja) 2001-07-23
ES2253750T3 (es) 2006-06-01

Similar Documents

Publication Publication Date Title
DK0835115T3 (da) 4-(2-(N-2-carboxamidoindo)aminoethyl)-benzensulfonamider eller -sulfonylurinstoffer som PDGF-antagonister
GB2311463B (en) Composition for inhibiting intimal hyperplasia using PDGF antagonists and heparin
ATE313324T1 (de) Verwendung von brefeldin a und deren derivate in der herstellung von arzneimittel zur behandlung von hyperplasie und verwandten erkrankungen
ATE253582T1 (de) Prodrogs und analoga von camptothecin und deren verwendung als arzneimittel
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
ATE293973T1 (de) Naphtylisoquinolinalkaloiden, diese enthaltende pharmazeutische zusammensetzungen und ihre verwendung zur behandlung von malaria
DK0680323T3 (da) Synergistisk kombination med antagonistvirkning ved NK1- og Nk2-receptorer.
EE04263B1 (et) Farmatseutiline kompositsioon piperidinoalkanoolantihistamiini ja selle derivaatide biosaadavuse suurendamiseks ning allergiliste reaktsioonide raviks patsiendil
EP1461056A4 (de) Verfahren zur herstellung und verwendung von polyoxyethyliertem rizinusöl in pharmazeutischen zusammensetzungen
WO2000078795A3 (en) Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)
EE04551B1 (et) Optiliselt aktiivne pridl-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis
DE69413009D1 (de) Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
ATE147936T1 (de) Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten
ATE183644T1 (de) Verwendung von 1,4-dihydropyridinderivaten in der prävention und therapie der atherosklerotischen degeneration von arterienwänden
ATE109137T1 (de) Pyridinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen.
Iwama et al. Discovery of a potent and selective αvβ3 integrin antagonist with strong inhibitory activity against neointima formation in rat balloon injury model
ATE99282T1 (de) 2-aminocarbonsaeuren und deren derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel.
DE69327074D1 (de) Substituierte 1,2,4-Triazine-3,5-Dion Derivate und diese enthaltende Arzneimittel, insbesondere zur Behandlung von Coccidiose
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung
ATE152911T1 (de) Verwendung von bilobalid und deren derivate zur behandlung von infektionen bei menschen und für eine solche anwendung geeignete pharmazeutische zusammensetzung
ITMI932468A0 (it) Nuovi difenilimidazoli utili nel trattamento di dislipidemia, arteriosclerosi e malattie coronariche procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
HU9802896D0 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
FR2661677B1 (fr) Derives heterocycliques d'acylaminothiazoles, leur preparation et compositions pharmaceutiques en contenant.
ITMI913398A1 (it) Derivati dell'eserolina ad attivita' anticolinesterasica procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0831807

Country of ref document: EP

REN Ceased due to non-payment of the annual fee